Market research
XE7C.F Cardiff Oncology, Inc
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 55M
- P/E ratio
- Not available
- Analyst target
- 25.33
- Dividend yield
- Not available
- Beta
- 1.42
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 55M
- P/E ratio
- Not available
- Analyst target
- 25.33
- Dividend yield
- Not available
- Beta
- 1.42
About
About Cardiff Oncology, Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Research context
Cardiff Oncology, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the XE7C.F discussion.
5 years, 6 months ago
Cardiff Oncology, Inc is currently in a long term downtrend where the price is trading 49.3% below its 200 day moving average.
From a valuation standpoint, the stock is 57.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 559.4.
Cardiff Oncology, Inc's total revenue rose by 28.8% to $119K since the same quarter in the previous year.
Its net income has dropped by 55.5% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 58.1% to $-5M since the same quarter in the previous year.
Based on the above factors, Cardiff Oncology, Inc gets an overall score of 2/5.